文献速递药物相互作用特殊人群用药

多价阳离子补充剂与BIC/FTC/TAF同服时实现HIV病毒学抑制:病例报告与文献回顾

Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature.
PubMed 文献 · Am J Health Syst Pharm · 2023-01-01

一例56岁女性HIV感染者,有袖状胃切除术史,启动比克替拉韦/恩曲他滨/丙酚替诺福韦(BIC/FTC/TAF)治疗,基线HIV病毒载量139,790拷贝/mL,CD4计数544 cells/mm3。因每日两次钙剂和复合维生素含多价阳离子,通过剂量分离策略设计给药方案避免相互作用,8周后病毒载量检测不到(<40拷贝/mL),CD4升至821 cells/mm3。

要点

  • 多价阳离子补充剂可与整合酶抑制剂结合影响抗病毒疗效。
  • 通过优化给药时间分离补充剂与BIC/FTC/TAF可减轻相互作用。
  • 本例8周后实现病毒学抑制且CD4计数提升。

核心结论

  • 通过注意每次给药时间并优化分离策略,可避免或减轻整合酶链转移抑制剂与营养补充剂中多价阳离子的相互作用。

研究设计与样本

  • 单例病例报告(56岁白人女性,袖状胃切除术后,HIV感染),结合文献回顾。

主要发现

  • 基线HIV病毒载量139,790 RNA copies/mL,CD4计数544 cells/mm3。
  • 启动BIC/FTC/TAF并采用剂量分离策略后8周,HIV病毒载量检测不到(<40 copies/mL),CD4计数升至821 cells/mm3。

临床怎么用

  • 对服用含多价阳离子补充剂的HIV患者,选用整合酶抑制剂方案时应设计剂量分离给药时间表。

局限性

  • 目前缺乏每日两次阳离子给药与BIC同服的指南,复合维生素同服指导也有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe a case report of antiretroviral regimen selection, with considerations for drug-supplement interactions, for a patient living with HIV with complicated nutrition needs. SUMMARY: A 56-year-old white female with a history of sleeve gastrectomy was initiated on coformulated bictegravir/emtricitabine/tenofovir alafenamide for treatment of HIV infection. Her baseline HIV viral load was 139,790 RNA copies/mL, and the baseline CD4 cell count was 544 cells/mm3. The patient additionally had a nutritional supplement regimen of twice-daily calcium and twice-daily multivitamins with minerals following sleeve gastrectomy. Due to binding interactions between polyvalent cations and bictegravir and the potential impact on antiretroviral efficacy, construction of a daily medication schedule to avoid interactions between the antiretroviral regimen and the supplements while promoting optimal dosing of each supplement was necessary; however there is currently no guidance on twice-daily cation dosing with coadministered bictegravir and limited guidance on multivitamin coadministration in this context. A review of the available literature on bictegravir interactions and pharmacokinetic parameters was performed. A dose separation strategy was utilized to design a regimen that maximized separation of doses of supplements from doses of bictegravir/emtricitabine/tenofovir alafenamide while minimizing interaction potential. At follow-up 8 weeks after regimen initiation, the HIV viral load was undetectable (<40 copies/mL) and the CD4 cell count had increased to 821 cells/mm3. CONCLUSION: Integrase strand transferase inhibitor interactions with polyvalent cations in nutritional supplements can be avoided or mitigated with attention to timing of each dose and optimizing separation strategies. This case report shows the potential for alleviating such interactions through optimal dose scheduling.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Buscemi L, Mossholder B. Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature. Am J Health Syst Pharm. 2023. PMID: 36306472. doi:10.1093/ajhp/zxac324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。